impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Diagnosis

 

Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren’s syndrome adults from a defined population

1, 2, 3, 4, 5, 6, 7

 

  1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  2. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  3. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. ykaneko.z6@keio.jp
  4. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  5. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  6. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  7. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

CER10753
2018 Vol.36, N°3 ,Suppl.112
PI 0157, PF 0164
Diagnosis

Free to view
(click on article PDF icon to read the article)

PMID: 29465360 [PubMed]

Received: 16/08/2017
Accepted : 04/12/2017
In Press: 15/02/2018
Published: 14/08/2018

Abstract

OBJECTIVES:
To identify biomarkers for disease activity in IgG4-related disease (IgG4-RD) and primary Sjögren’s syndrome (pSS).
METHODS:
Forty-three consecutive treatment-naïve patients with IgG4-RD, 62 patients with pSS, and 5 patients with sicca syndrome were enrolled. IgG4-RD and pSS disease activity was assessed based on the IgG4-RD responder index (IgG4-RD RI) and EULAR Sjögren’s Syndrome Disease Activity Index (ES- SDAI), respectively. The associations of biomarkers with disease activity were examined.
RESULTS:
Comparison of the three dis- eases identified the serum levels of IgG, IgG4, IgG4/IgG ratio, IgE, and soluble interleukin-2 receptor (sIL-2R) for IgG4-RD and the serum levels of IgM and sIL-2R and lymphocyte counts for pSS as potential biomarkers of disease activity. Among these, serum sIL-2R levels correlate with baseline IgG4-RD RI scores and the number of affected organs in IgG4-RD (ρ=0.74, p<0.0001 and ρ=0.75, p<0.0001, respectively). Serum sIL-2R levels also correlate with ESSDAI scores and the number of af- fected organs in pSS (ρ=0.67, p<0.0001 and ρ=0.41, p<0.0001, respectively). Receiver operating characteristic curve analysis suggested serum sIL-2R levels as an efficient biomarker to distinguish the presence of extra-dacryosialadenitis involvements in IgG4-RD with a cut-off value of 424 U/mL (AUC=0.93, p<0.0001), and in pSS with 452 U/mL (AUC=0.89, p<0.0001). Serum sIL-2R levels decreased significantly after treatment in patients with IgG4-RD and pSS.
CONCLUSIONS:
Serum sIL-2R levels are a potentially valuable biomarker for evaluating disease activity and treatment response in IgG4-RD and pSS.

Rheumatology Article

Rheumatology Addendum